

Reference Data

¹³C NMR Spectral Characterization of Some Antimalarial Tricyclic Quinolone Derivatives

Jose N. Dominguez,^{1*} Jaime E. Charris¹,
William Basante¹ and Bernardo Mendez²

¹ Laboratorio de Síntesis Orgánica, Facultad de Farmacia,
Universidad Central de Venezuela, Caracas 1051, Venezuela

² Laboratorio de RMN, Escuela de Química, Facultad de
Ciencias, Universidad Central de Venezuela, Caracas, Venezuela

Received 12 June 1997; revised 7 October 1997; accepted 8 October 1997

ABSTRACT: We report the ¹³C NMR chemical shifts of some active quinolones against *Plasmodium falciparum*, namely 3-amino-9-phenyl-1*H*-pyrazolo[3,4-*b*]quinolones and 2,4-diamino-10-phenylpyrimido[4,5-*b*]quinolones. They were characterized and assigned on the basis of ¹³C-¹H (short and long-range) correlated spectra. © 1998 John Wiley & Sons, Ltd.

KEYWORDS: NMR; ¹³C NMR; quinolones; antimalarial

INTRODUCTION

Malaria remains one of the most important infectious disease problems in the world. Hundreds of millions of cases of malaria occur each year, of which nearly two million are fatal, mostly children.¹ Efforts to control this endemia have been unsuccessful and the development of new agents active against resistant strains of malaria has become an urgent need.² In recent years, there have been a number of reports concerned with the synthesis and biological activity of some new and potent antimalarial agents against *Plasmodium falciparum*.³ Our synthetic efforts have been centered around a series of steps which were used to synthesize some new quinolone analogues with promising antimalarial activity, **1–18** (Fig. 1).⁴ This paper presents ¹³C NMR data for these quinolones.




Figure 1. Structures of quinolones **1–18**.

* Correspondence to: J. N. Dominguez, Laboratorio de Síntesis Orgánica, Facultad de Farmacia, Universidad Central de Venezuela, Caracas 1051, Venezuela.

Contract/grant sponsor: Consejo de Desarrollo Científico y Humanístico (CDCH-UCV); Contract/grant number: 06-30-3402-96.

Contract/grant sponsor: Instituto de Investigaciones Farmacéuticas, Facultad de Farmacia, UCV; Contract/grant number: IIF/01-94.

Contract/grant sponsor: Consejo de Estudio de Postgrado, UCV.

EXPERIMENTAL

Compounds

The quinolones **1–18** were synthesized according to the literature.⁴ The structures and purities of the compounds were confirmed by their melting points, elemental analyses, mass spectra (LSIMS) and ¹H NMR spectra.

NMR spectroscopy

All NMR spectra were recorded on a Jeol JNM EX 270 Fourier transform NMR spectrometer in DMSO-*d*₆ solutions; tetramethylsilane (TMS) was used as an internal standard. The instrument was equipped with a 5 mm broadband probe head. The processing was performed using the program DELTA V1.6, running on a Silicon Graphics workstation.

In 1D ¹³C experiments, the parameters were as follows: spectral window, 250 ppm; width of 30° pulse, 2.8 μs; relaxation delay, 2 s; and number of scans, 2000–3000. All 2D NMR spectra were obtained using standard JEOL software.

Homonuclear ¹H-¹H COSY experiments were typically performed with a spectral width of 4000 Hz, relaxation delay 1.5 s, mixing pulse 90°, number of increments 64 and a number of scans of 16. The spectra were collected as 256 × 64 blocks of data and were processed by sinusoidal multiplication in each dimension, followed by symmetrization of the final data matrix. The heteronuclear ¹H-¹³C HETCOR experiments were carried out with a spectral width of 17 000 Hz for ¹³C (*F*₂) and 4000 Hz for ¹H (*F*₁). The spectra were acquired with 1028 × 64 data points. The data were processed by exponential multiplication (LB = 3 Hz) in *F*₂ and sinusoidal multiplication in *F*₁ and zero filling was applied in *F*₁. The mixing delay for single-bond correlation was 3.4 ms and for long-range bond correlation it was 70 ms and the relaxation delay was 1.5 s.

RESULTS AND DISCUSSION

¹³C NMR chemical shift assignments are given in Tables 1 and 2. The resonances were assigned with the data provided by ¹³C-¹H (short- and long-range) HETCOR experiments. The long-range correlations were particularly useful in making many of the carbon assignments. The ¹H NMR for **10–18** included two doublets around 7.6 and 9.5 ppm which were assigned to the amine group linked to C-4 and having a ²*J* (4.7 Hz) (see Fig. 2). Earlier investigation on related compounds had shown in x-ray crystallography good correlations in their distance for the formation of hydrogen bonding.⁵ This provides clear evidence of the presence of hydrogen bonding between one of the NH₂ protons and the carbonyl group attached to the carbon at C-5. Hence the availability of these techniques provides an important tool which has stimulated much interest, because of the biological properties of these quinolones. In this work we found that structures with hydrogen bonding, **10–18**, do not have antimalarial activity. However, compounds **1–9**, without hydrogen bonding, were active as antimalarials. These results might be taken into consideration in further studies.

Acknowledgments

We thank the Consejo de Desarrollo Científico y Humanístico (CDCH-UCV), project No. 06-30-3402-96, the Instituto de Investigaciones Farmacéuticas, Facultad de Farmacia, UCV, project No. IIF/1-94, and Consejo de Estudio de Postgrado, UCV, for financial support.

Reference Data

Table 1. ^{13}C NMR chemical shifts (ppm relative to internal TMS) for 3-amino-9-phenylpyrazolo[3,4-*b*]quinolones 1–9^a

Carbon	1 (R = H)	2 (R = 4'-OMe)	3 (R = 3'-OMe)	4 (R = 2'-Me)	5 (R = 4'-Br)	6 (R = 4'-Cl)	7 (R = 4'-F)	8 (R = 2',4'-Cl ₂)	9 (R = 3'-CF ₃)
C-3	152.13	152.07	151.88	151.64	151.76	151.63	152.57	151.30	151.96
C-3a	95.15	95.30	95.19	95.38	95.21	95.25	95.17	94.88	95.21
C-4	174.78	174.63	174.68	174.82	174.60	174.59	174.80	174.75	174.67
C-4a	122.77	122.90	122.78	122.69	122.90	122.90	122.87	122.83	122.96
C-5	126.36	126.29	126.28	126.48	126.40	126.41	126.38	126.56	126.32
C-6	120.44	120.30	120.45	120.44	120.73	120.71	120.61	120.95	120.79
C-7	132.78	132.72	132.77	132.46	132.88	132.87	132.84	133.16	132.97
C-8	115.35	115.42	115.49	114.76	115.28	115.27	115.29	114.69	115.12
C-8a	143.74	143.71	143.67	143.15	143.31	143.36	143.67	142.67	143.34
C-9a	148.63	148.75	148.63	148.67	149.11	149.00	148.60	148.69	148.67
1'	138.18	139.95	139.16	137.35	137.81	136.93	134.25a	135.13	138.95
2'	129.29	131.08	115.16	133.01	132.42	130.82	132.13b	134.48	126.36e
3'	130.75	115.89	161.20	129.71	133.78	132.10	117.64c	133.16	133.23f
4'	130.04	159.65	115.28	130.31	122.37	133.82	162.27d	135.04	127.30g
5'	130.75	131.08	121.92	129.76	133.42	132.10	117.64	134.19	131.53
6'	129.29	115.89	120.73	128.41	132.46	130.82	132.13	129.93	131.73
CH ₃		56.02	55.8	17.46					
CF ₃									123.16h

^a $J_a = 3.4$; $J_b = 9.5$; $J_c = 22.4$; $J_d = 243$; $J_e = 3.82$; $J_f = 33.27$; $J_g = 3.27$; $J_h = 272.9$ Hz.**Table 2.** ^{13}C NMR chemical shifts (ppm relative to internal TMS) for 2,4-diamino-10-phenylpyrimido[4,5-*b*]quinolones 10–18^a

Carbon	10 (R = H)	11 (R = 4'-OMe)	12 (R = 3'-OMe)	13 (R = 2'-Me)	14 (R = 4'-Br)	15 (R = 4'-Cl)	16 (R = 4'-F)	17 (R = 2',4'-Cl ₂)	18 (R = 3'-CF ₃)
C-2	165.25	165.29	165.24	165.30	165.19	165.20	165.24	165.14	165.18
C-4	159.43	159.51	159.35	158.92	159.35	159.40	159.54	159.00	159.48
C-4a	93.52	93.62	93.51	93.48	93.51	93.51	93.55	93.37	95.54
C-5	176.32	176.32	176.32	176.31	176.31	176.32	176.33	176.31	176.36
C-5a	122.69	122.60	122.67	122.85	122.80	122.79	122.74	123.21	122.84
C-6	126.23	126.18	126.14	126.41	123.41	123.42	122.43	126.52	126.36
C-7	130.63	131.45	131.30	131.89	126.29	126.29	126.26	130.82	131.84
C-8	133.29	133.25	133.30	133.61	133.41	133.41	133.36	133.93	133.47
C-9	117.23	117.37	117.35	116.48	117.14	117.14	117.18	116.28	116.92
C-9a	142.41	142.79	142.31	141.50	142.08	142.14	142.42	140.94	142.14
C-10a	163.43	163.48	163.48	137.86	163.37	163.68	163.40	163.52	163.34
1'	139.00	137.73	140.13	137.86	138.35	137.90	135.17a	135.36	139.86
2'	130.31	131.25	114.89	136.87	132.72	130.69	132.49b	134.61	126.18e
3'	130.63	115.69	161.08	123.40	133.63	132.38	117.46c	133.92	131.35f
4'	129.19	159.54	115.24	129.51	122.41	133.77	162.30d	123.45	127.47g
5'	130.63	131.25	122.66	130.11	133.63	132.38	117.46	129.80	135.04
6'	130.31	115.69	122.28	128.32	132.72	130.69	132.49	129.93	131.11
CH ₃		55.92	55.94	17.57					
CF ₃									124.40h

^a $J_a = 1.72$; $J_b = 8.7$; $J_c = 22.5$; $J_d = 242.2$; $J_e = 3.84$; $J_f = 32.38$; $J_g = 3.83$; $J_h = 271.7$ Hz.

Reference Data




Figure 2. COSY spectrum of 14.

REFERENCES

1. (a) *Weekly Epidemiol. Rec., WHO* **71**, (1–4) 17 (1996); (b) J. A. Walsh, *Ann. N.Y. Acad. Sci.* **569**, 1 (1989).
2. (a) S. C. Oaks, V. S. Mitchell, G. W. Pearson and C. J. Carpenter, *Malaria: Obstacles and Opportunities*. National Academy Press, Washington, DC (1991); (b) J. S. Moran and K. W. Bernard, *J. Am. Med. Assoc.* **262**, 245 (1989).
3. (a) D. C. Hooper and J. S. Wolfson, *Antimicrob. Agents Chemother.* **28**, 716 (1985); (b) P. S. Sarma, *Ann. Intern. Med.* **111**, 336 (1989); (c) K. D. Tripathi, A. K. Sharma, N. Valecha and S. Biswas, *Indian J. Malariol.* **30**, 67 (1993); (d) R. Li, X. Chem, B. Gong, J. N. Domínguez, E. Davidson, R. E. Davidson, R. E. Miller, E. Nuzum, J. M. Karle, J. H. McKerrow, G. L. Kenyon and F. Cohen, *J. Med. Chem.* **38**, 5031 (1995); (e) J. N. Domínguez, J. Charris, L. Iarrusso, S. López, G. Lobo and F. Riggione, *Farmaco* **51**, 781 (1996); (f) J. N. Domínguez, S. López, J. Charris, L. Iarrusso, G. Lobo, A. Semenov, J. E. Olson and P. J. Rosenthal, *J. Med. Chem.* **40**, 2726 (1997).
4. J. N. Domínguez, W. Basante, J. Charris and F. Riggione, *Farmaco* **51**, 407 (1996).
5. (a) J. N. Domínguez and J. Charris, *Org. Prep. Proced. Int.* **25**, 683 (1993); (b) M. V. Caparelli, J. Charris and D. Cascio, *Acta Crystallogr., Sect. A* **49**, 131 (1993).